Modeling of systemic inflammatory response syndrome by chemical induction of colon injury in rats

Our objective was to develop a model of systemic inflammatory response syndrome (SIRS) by chemical induction of colon injury and antibiotic-associated intestinal dysbiosis in rats with primary visceral obesity (PVO) for studies of myocardial resistance to ischemia-reperfusion injury. The experiments were performed with adult Wistar male rats with PVO under improved conditions of a conventional animal clinic. The chemically induced inflammatory colon disease (CIICD) was accomplished by intragastric administration of a mixture of broad-spectrum antimicrobial agents (AMA) for 3 days. Five days later, immunological and biochemical studies were carried out, as follows: composition of the intestinal microbiota in feces and shortchain fatty acids in blood, morphological changes in the structure of the colon, hemodynamic parameters and myocardial stability with modified Langendorff system. In PVO rats, the mass of visceral fat deposits and the content of lipopolysaccharides (LPS) in the blood were significantly increased when giving them fatcarbohydrate diet (FCD). In animals with CIICD, in addition to LPS, there was a significant increase in proinflammatory cytokine concentration (TNF, IL-8, MCP-1), and after oral administration of the AMA mixture, pronounced disturbances of food behavior and evacuatory function of gastrointestinal tract, deep destructive changes in colon, as well as qualitative and quantitative composition of intestinal microbiota with characteristics typical to the first-grade dysbiosis. High levels were shown for IL-8 cytokine only. An increase in acetic and propionic acid concentrations were shown in blood in animals with CIICD, and, to a greater extent, in rats with antibiotic-induced dysbiosis (AID). FCD was followed by significantly reduced levels of lactobacilli and bifidobacteria in colonic contents. CIICD leads to detection of Escherichia coli, and intestinal dysbiosis leads to the manifestation of Proteus. A comorbid combination of pathological changes in the immune and digestive systems caused a significant increase in the area of myocardial necrosis (by 35 percent) in isolated heart by, thus presuming decreased myocardial resistance to ischemia-reperfusion injury (IRI). The SIRS model induced by chemical trauma to large intestine is aggravated by the introduction of AMAs mixture, and it is characterized by a controlled change in inflammatory markers. Deterioration of morphofunctional characteristics in isolated heart included decrease in resistance to IRI seems to correspond to acute inflammatory bowel disease with induced intestinal dysbiosis. This model can be used in experimental medicine in the field of cardiology, endomicroecology, gastroenterology, and immunology.

cytokines, inflammatory colon disease, antibiotic-induced dysbiosis, isolated heart, infarct size

1. Averina O.V., Ermolenko E.I., Ratushniy A.Yu., Tarasova E.A., Borshchev Yu.Yu., Leontieva G.F., Kramskaya T.A., Kotyleva M.P., Danilenko V.N., Suvorov A.N. Influence of probiotics on cytokine production in the in vitro and in vivo systems. Meditsinskaya immunologiya = Medical Immunology (Russia), 2015, Vol. 17, no. 5, pp. 443-454. (In Russ.) doi: 10.15789/1563-0625-2015-5-443-454.

2. Borshchev Yu.Yu., Ermolenko E.I. Metabolic syndrome and intestinal microecology. Translyatsionnaya meditsina = Translational Medicine, 2014, no. 1, pp. 19-28. (In Russ.)

3. Borshchev Yu.Yu., Minasian S.M., Burovenko I.Yu., Borshchev V.Yu., Galagudza M.M. Antibiotic-induced intestinal dysbiosis and myocardial tolerance to ischemia-reperfusion injury in rats with different microbiological status. Eksperimentalnaya i klinicheskaya gastroenterologiya = Russian Journal of Experimental and Clinical Gastroenterology, 2018, no. 10 (158), pp. 62-67. (InRuss.)

4. Borshchev Yu.Yu., Minasian S.M., Burovenko I.Yu., Ermolenko E.I., Suvorov A.N., Galagudza M.M. Influence of probiotic strain E. Faecium L3 on myocardial tolerance to ischemiareperfusion injury in the model of antibiotic-induced intestinal dysbiosis. Rossiyskiy fiziologicheskiy zhurnal im. I.M. Sechenova = Russian Journal of Physiology, 2016, Vol. 102, no. 11, pp. 1323-1332. (In Russ.)

5. Borshchev Yu.Yu., Sinitsa A.V., Zakharchenko M.M., Borshchev Vu.Yu., Burovenko I.Yu., Galagudza M.M. Еffect of antiobiotic-induced disbiosis and its correction with probiotics on myocardial tolerance to ischemia-reperfusion injury in SPF rats. Byulleten eksperimentalnoy biologii i meditsiny = Bulletin of Experimental Biology and Medicine, 2018, Vol. 166, no. 10, pp. 426-430. (In Russ.)

6. Jawetz E., Melnick J.L., Adelberg E.A. Review of medical microbiology: in 3 vol. Engl. transl. Ed. T.V. Peradze. Moscow: Medicine, 1982, Vol. 2, pp. 9-18.

7. Intestinal dysbiosis. Guidelines for diagnosis and treatment. Ed. E.I. Tkachenko, A.N. Suvorov. St. Petersburg: InformMed, 2009. 276 p.

8. Knyazev O.V., Shkurko T.V., Fadeeva N.A., Bakulin I.G., Bordin D.S. Epidemiology of chronic inflammatory bowel disease. Yesterday, today, tomorrow. Eksperimentalnaya i klinicheskaya gastroenterologiya = Russian Journal of Experimental and Clinical Gastroenterology, 2017, no. 3 (139), pp. 4-12. (In Russ.)

9. Korolev D.V., Alexandrov I.V., Galagoudza M.M., Syrensky A.V., Sonin D.L., Egorova E.I. Automation of data acquisition and processing in physiological experiments. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya = Regional Hemodynamics and Microcirculation, 2008, Vol. 7, no. 2 (26), pp. 79-84. (In Russ.)

10. Minasyan S.M., Badrikhanova L.R., Galagudza M.M., Kurapeev D.I. Comparative research of protective effect of a hypothermia, ischemic preconditioning and the modified cardioplegic solutions at ischemia-reperfusion of the rat’s isolated heart. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya = Regional Hemodynamics and Microcirculation, 2008, Vol. 7, no. 2, pp. 72-78. (In Russ.)

11. Osikov M.V., Simonyan E.V., Bakeeva A.E., Boyko M.S., Bivalkevich V.A. Experimental modeling and future directions of homeostasis correction in inflammatory bowel diseases. Aspirantskiy vestnik Povolzhya = Postgraduate Bulletin of the Volga Region, 2018, no. 1-2, pp. 153-160. (In Russ.)

12. Pikunov D.Yu., Rybakov E.G., Golovenko E.G. Pseudomembranous colitis (literature review). Koloproktologiya = Coloproctology, 2010, no. 2 (32), pp. 55-60. (In Russ.)

13. Rasenack J., Sitkin S.I. Inflammatory bowel diseases: a practical guide. 7th edition, revised and enlarged. Moscow: Forte print, 2014. 108 p.

14. Fiocchi С. Etiopathogenesis of inflammatory bowel disease. Koloproktologiya = Coloproctology, 2015, no. 1 (51), pp. 5-20. (In Russ.)

15. Adams S.D., Mercer D.W. Fulminant Clostridium difficile colitis. Curr. Opin. Crit. Care, 2007, Vol. 13, no. 4, pp. 450-455.

16. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 2007, Vol. 369, no. 9573, pp. 1641-1657.

17. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A, Schein R.M., Sibbald W.J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 1992, Vol. 101, no. 6, pp. 1644-1655.

18. Dobner J., Kaser S. Body mass index and the risk of infection – from underweight to obesity. Clin. Microbiol. Infect., 2018, Vol. 24, no. 1, pp. 24-28.

19. Ermolenko E., Rybalchenko O., Borshev Y., Tarasova E., Kramskaya T., Leontieva G., Kotyleva M., Orlova O., Abdurasulova I., Suvorov A. Influence of monostrain and multistrain probiotics on immunity, intestinal ultrastructure and microbiota in experimental dysbiosis. Benef. Microbes, 2018, Vol. 9, no. 6, pp. 937-949.

20. Fallucca F., Fontana L., Fallucca S., Pianesi M. Gut microbiota and Ma-Pi 2 macrobiotic diet in the treatment of type 2 diabetes. World J. Diabetes, 2015, Vol. 6, no. 3, pp. 403-411.

21. Kumar M., Dhaka P., Vijay D., Vergis J., Mohan V., Kumar A., Kurkure N.V., Barbuddhe S.B., Malik S.V., Rawool D.B. Antimicrobial effects of Lactobacillus plantarum and Lactobacillus acidophilus against multidrugresistant enteroaggregative Escherichia coli. Int. J. Antimicrob. Agents, 2016, Vol. 48, no. 3, pp. 265-270.

22. Lam V., Su J., Koprowski S., Hsu A., Tweddell J.S., Rafiee P., Gross G.J., Salzman N.H., Baker J.E. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J., 2012, Vol. 26, pp. 1727-1735.

23. Martín R., Chain F., Miquel S., Motta JP., Vergnolle N., Sokol H., Langella P. Using murine colitis models to analyze probiotics-host interactions. FEMS Microbiol. Rev., 2017, Vol. 41, no. 1, pp. S49-S70.

24. Saad M.J., Santos A., Prada P.O. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology (Bethesda), 2016, Vol. 31, no. 4, pp. 283-293.

25. Sanmiguel C., Gupta A., Mayer E.A. Gut microbiome and obesity: a plausible explanation for obesity. Curr. Obes. Rep., 2015, Vol. 4, no. 2, pp. 250-261.

26. Tordjman J., Guerre-Millo M., Clement K. Adipose tissue inflammation and liver pathology in human obesity. Diabetes Metab., 2008, Vol. 34, no. 6, Pt 2, pp. 658-663.

27. Zhu H., Sun X., Wang D., Hu N., Zhang Y. Doxycycline ameliorates aggregation of collagen and atrial natriuretic peptide in murine post-infarction heart. Eur. J. Pharmacol., 2015, Vol. 754, pp. 66-72.